Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 2/20 | 0.54 |
| ▸ | NQO2 | P16083 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | NCK1 | P16333 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11011819 | 0.78 | TEAD4 (0.44) | ENPP2ALDH1A1HSD17B10ALOX15TSHR | |
| SCHEMBL3078778 | 0.74 | ENPP2 (0.58) | ENPP2ALDH1A1HSD17B10ALOX15TSHR | |
| SCHEMBL11985802 | 0.73 | ENPP2 (0.44) | ENPP2NQO2ALDH1A1HSD17B10ALOX15 | |
| SCHEMBL9927345 | 0.70 | NQO2 (0.85) | NQO2ALDH1A1CYP1A2KDM4EL3MBTL1 | |
| SCHEMBL2756741 | 0.70 | NQO2 (0.85) | NQO2ALDH1A1CYP1A2KDM4EL3MBTL1 | |
| SCHEMBL961191 | 0.70 | ENPP2 (0.54) | ENPP2ALDH1A1HSD17B10ALOX15TSHR | |
| SCHEMBL6154461 | 0.70 | ENPP2 (0.54) | ENPP2ALDH1A1HSD17B10ALOX15TSHR | |
| SCHEMBL8326170 | 0.70 | ENPP2 (0.54) | ENPP2ALDH1A1HSD17B10ALOX15TSHR | |
| SCHEMBL298552 | 0.70 | ENPP2 (0.54) | ENPP2ALDH1A1HSD17B10ALOX15TSHR | |
| SCHEMBL13928717 | 0.70 | ENPP2 (0.54) | ENPP2ALDH1A1HSD17B10ALOX15TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 430 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2501236-B1 | N-[2-fluoro-3-(4-amino-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-phenyl]-4-benzenesulfonamide derivatives as Raf protein kinase modulators for the treatment of cancer | PLEXXIKON INC (US) | 2017-03-29 | — | — | EP | claimed |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2015-10-15 | — | — | US | claimed |
| EP-2350090-B1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC (CA) | 2015-06-03 | — | — | EP | claimed |
| US-8673928-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2014-03-18 | — | — | US | claimed |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2012-11-22 | — | — | US | claimed |
| US-8263606-B2 | Spiro-oxindole compounds and their use as therapeutic agents | XENON PHARMACEUTICALS INC. (CA) | 2012-09-11 | — | — | US | claimed |
| EP-2350090-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | Xenon Pharmaceuticals Inc. (CA) | 2011-08-03 | — | — | EP | claimed |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | ASTRAZENECA AB (SE) | 2011-06-30 | — | — | US | claimed |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | PLEXXIKON INC. | 2011-06-23 | — | — | US | claimed |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS INC. (CA) | 2010-06-03 | — | — | US | claimed |
| EP-2190838-A1 | CANNABINOID RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2010-06-02 | — | — | EP | claimed |
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | ASTRAZENECA AB (SE) | 2010-05-06 | — | — | US | claimed |
| WO-2010045251-A2 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | XENON PHARMACEUTICALS, INC. (CA) | 2010-04-22 | — | — | WO | claimed |
| US-20090062251-A1 | Novel Compounds 002 | ASTRAZENECA AB (SE) | 2009-03-05 | — | — | US | claimed |
| WO-2009024819-A1 | CANNABINOID RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2009-02-26 | — | — | WO | claimed |
| WO-2008036022-A1 | TETRAHYDRO-LH-PYRIDO[3,4-B] INDOLE DERIVATIVES AS CB1 RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2008-03-27 | — | — | WO | claimed |
| EP-1863810-A1 | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1' RECEPTOR LIGANDS | AstraZeneca AB (SE) | 2007-12-12 | — | — | EP | claimed |
| WO-2006101434-A1 | NOVEL TETRAHYDRO-1H-PYRIDO [4,3-b] INDOLE DERIVATIVES AS CB1’ RECEPTOR LIGANDS | ASTRAZENECA AB (SE) | 2006-09-28 | — | — | WO | claimed |
| EP-4071140-B1 | CFTR REGULATORS AND METHODS OF USE THEREOF | UNIV CALIFORNIA (US) | 2024-07-03 | — | — | EP | disclosed |
| WO-1994024080-A1 | PROGESTERONE RECEPTOR AGONIST AND ANTAGONISTS | LIGAND PHARMACEUTICALS INC. (US) | 1994-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062251-A1 | Novel Compounds 002 | OPRL1, OPRK1, OPRM1 | ENPP2 1238/4885NQO2 785/4885ALDH1A1 517/4885 |
| US-20110160180-A1 | Cannabinoid Receptor Ligands | CNR1, CNR2, OPRL1 | ENPP2 830/4885NQO2 2502/4885ALDH1A1 2240/4885 |
| US-20110152258-A1 | Compounds and Methods for Kinase Modulation, and Indications Therefor | BRAF, KRAS, RAF1 | ENPP2 3466/4885NQO2 2760/4885ALDH1A1 1181/4885 |
| US-20150291623-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | ENPP2 1248/4885NQO2 430/4885ALDH1A1 1020/4885 |
| US-20100113502-A1 | Novel Tetrahydro-1H-Pyrido[4,3-b] Indole Derivatives as CB1 Receptor Ligands | CNR1, CNR2, OPRL1 | ENPP2 1446/4885NQO2 2712/4885ALDH1A1 1706/4885 |
| US-20120295897-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USES AS THERAPEUTIC AGENTS | TRPV3, TRPC3, TRPV1 | ENPP2 1123/4885NQO2 428/4885ALDH1A1 1005/4885 |
| US-20100137299-A1 | SPIRO-OXINDOLE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS | TRPV3, TRPV1, TRPC3 | ENPP2 1248/4885NQO2 430/4885ALDH1A1 1020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.